Perceived Barriers to Accessing Tuberculosis Care Among Multidrug Resistant Tuberculosis (MDR-TB) Patients: A Qualitative Study in Indonesia
DOI:
https://doi.org/10.61841/nd3xnm71Keywords:
Barriers, Multidrug-resistant tuberculosis, Patients’ perspective, Qualitative studyAbstract
Indonesia has one of the highest MDR-TB burdens in the world. The success rate of MDR-TB treatment in Indonesia is still low. Indonesia changed the health system policy, which is called the National Health Insurance, in 2013. The purpose of this study is to provide a description from the point of view of MDR-TB patients about barriers during their treatment, although the health system in Indonesia has changed. This study used qualitative semi- structured in-depth questions. Fifteen MDR-TB patients were interviewed concerning the barriers during their treatment. Purposive sampling was used to recruit study participants. Thematic analysis was used to identify and analyse the main topics. Topics generated were financial barriers, poor service, inadequate hospital facilities, ineffective communication of patient-provider, stigma, and lack of social support. Each theme was from verbatim transcripts defined during the coding process. Codes and themes were developed to coincide with data collection. Periodic monitoring of aid disbursements, improvement of hospital services including health workers and facilities, increased social support, increased knowledge and home-based MDR-TB service programs can be implemented to reduce the perceived barriers for MDR-TB patients during treatment.
Downloads
References
[1] G. Report and O. N. Surveillanceresponse, “WHO. Multidrug and extensively drug-resistant TB (M/XDR- TB) Global report on Surveillance and Response,” 2010.
[2] WHWHO treatment guidelines for drug- resistant tuberculosis 2016O, “WHO treatment guidelines for drug- resistant tuberculosis 2016,” World Heal. Organ., no. October, 2016.
[3] K. L. Bieh, R. Weigel, and H. Smith, “Hospitalized care for MDR-TB in Port Harcourt, Nigeria: A qualitative study,” BMC Infect. Dis., vol. 17, no. 1, pp. 1–9, 2017, doi: 10.1186/s12879-016-2114-x.
[4] S. van den Hof, D. Collins, F. Hafidz, D. Beyene, A. Tursynbayeva, and E. Tiemersma, “The socioeconomic impact of multidrug resistant tuberculosis on patients: Results from Ethiopia, Indonesia and Kazakhstan,” BMC Infect. Dis., vol. 16, no. 1, 2016, doi: 10.1186/s12879-016-1802-x.
[5] W. I.F. et al., “Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders,” Int J Tuberc Lung Dis, vol. 21, no. 6, pp. 603–609, 2017, doi: http://dx.doi.org/10.5588/ijtld.17.0135.
[6] R. D. Deshmukh et al., “Patient and provider reported reasons for lost to follow up in MDRTB treatment: A qualitative study from a drug resistant TB Centre in India,” PLoS One, vol. 10, no. 8, pp. 1–11, 2015, doi: 10.1371/journal.pone.0135802.
[7] S. Horter et al., “"Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis.,” BMC Health Serv. Res., vol. 14, p. 81, 2014, doi: 10.1186/1472-6963-14-81.
[8] S. C. Baral, Y. Aryal, R. Bhattrai, R. King, and J. N. Newell, “The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: Mixed method qualitative and pilot intervention studies,” BMC Public Health, vol. 14, no. 1, 2014, doi: 10.1186/1471-2458-14-46.
[9] R. Departemen Kesehatan, “Rencana Aksi Nasional Programmatic Management of Drug resistance Tuberculosis Pengendalian Tuberkulosis Indonesia : 2011-2014,” Prorammatic Manag. Drug Resist. Tuberc., pp. 2011–2014, 2011.
[10] Dinas Kesehatan Kota Surabaya, “Profil Dinas Kesehatan Kota Surabaya,” Dinas Kesehat., p. 163, 2017.
[11] N. R. Gandhi et al., “Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis,” Lancet, vol. 375, no. 9728, pp. 1830–1843, 2010, doi: 10.1016/S0140-
6736(10)60410-2.
[12] S. Horter et al., “Where there is hope: A qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan,” BMC Infect. Dis., vol. 16, no. 1, pp. 1–15, 2016, doi: 10.1186/s12879-016-1723-8.
[13] R. D. Tristiana, A. Yusuf, R. Fitryasari, S. D. Wahyuni, and H. E. Nihayati, “Perceived barriers on mental health services by the family of patients with mental illness,” Int. J. Nurs. Sci., vol. 5, no. 1, pp. 63–67, 2018, doi: https://doi.org/10.1016/j.ijnss.2017.12.003.
[14] P. Soepandi, “Output of Treatment and Cost Variations of TB-MDR/XDR with PMDTDI Strategy in RSUP Persahabatan,” J. Adm. Kebijak. Kesehat., vol. 1, no. 1, pp. 19–25, 2016.
[15] C. Hutchison, M. S. Khan, J. Yoong, X. Lin, and R. J. Coker, “Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China,” BMC Public Health, vol. 17, no. 1, pp. 1–11, 2017, doi: 10.1186/s12889-017-4089-y.
[16] L. M. Ibrahim et al., “Health care workers’ knowledge and attitude towards TB patients under Direct Observation of Treatment in Plateau state Nigeria, 2011,” Pan Afr Med J., vol. 18, no. 8, 2014, doi: 10.11694/pamj.supp.2014.18.1.3408.
[17] P. J. Jaiswal A, Singh V, Ogden JA, “Adherence to tuberculosis treatment: lesson from the urban setting of Delhi, India,” Trop. Med. Int. Heal., vol. 8, no. 7, pp. 625–633, 2003.
[18] R. E. Sulistyono, T. Susanto, and R. D. Tristiana, “Barriers in Tuberculosis Treatment in Rural Areas (Tengger, Osing and Pandalungan) in Indonesia Based on Public Health Center Professional Workers Perspectives: a Qualitative Research,” J. Ners, vol. 14, no. 1, pp. 62–68, 2019, doi: http://dx.doi.org/10.20473/jn.v14i1.10270.
[19] A. Nandkeshav, K. Kalpana, R. Mangesh, J. Akanksha, and B. Balaji, “Patients’ Waiting Time and Their Satisfaction of Health Care Services Provided at Outpatient Department of Government Medical College, Nanded (Maharashtra, India),” IJHSR, vol. 4, no. 4, pp. 21–27, 2014.
[20] E. J. Murray, V. A. Bond, B. J. Marais, P. Godfrey-Faussett, H. M. Ayles, and N. Beyers, “High levels of
vulnerability and anticipated stigma reduce the impetus for tuberculosis diagnosis in Cape Town, South Africa,” Heal. Policy Plan., vol. 28, pp. 410–418, 2013, doi: 10.1093/heapol/czs072.
[21] S. A. Munro, S. A. Lewin, H. J. Smith, M. E. Engel, A. Fretheim, and J. Volmink, “Patient adherence to tuberculosis treatment: a systematic review of qualitative research,” PLoS Med, vol. 4, p. e238, 2007.
[22] V. K. Cubaka et al., “‘He should feel your pain’: Patient insights on patient–provider communication in Rwanda,” African J. Prim. Heal. Care Fam. Med., vol. 10, no. 1, 2018, doi: https://doi.org/10.4102/phcfm.v10i1.1514.
[23] W. Ssengooba et al., “Patient satisfaction with TB care clinical consultations in Kampala: a cross sectional study,” Afr Heal. Sci., vol. 16, no. 4, pp. 1101–1108, 2016, doi: 10.4314/ahs.v16i4.28.
[24] B. Chen et al., “Social support received by multidrug-resistant tuberculosis patients and related factors: a cross-sectional study in Zhejiang Province, People’s Republic of China,” Patient Prefer Adherence., vol. 10, 2016, doi: 1063–1070.
[25] R. E. Sulistyono, T. Susanto, and R. D. Tristiana, “Patients Experience and Perception in Preventing Tuberculosis Transmission in Rural Areas: A Qualitative Research,” J. Keperawatan Padjadjaran, vol. 8, no. 1, 2020, doi: 10.24198/jkp.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
